Table 2. Response rates Entire study... | American Society of Hematology

Table 2.

Response rates

Entire study cohort (N = 16)	Monotherapy				Monotherapy + induction∗
	Day 35		Day 77		Day 77
	n	%	n	%	n	%
CR	3	18.8	3	18.8	6	37.5
PR	2	13.5	0	0	1	6.3
No response†	11	67.7	13	81.2	9	56.2
ORR (CR + PR)	5	31.3	3	18.8	7	43.8

Entire study cohort (N = 16)	Monotherapy				Monotherapy + induction∗
	Day 35		Day 77		Day 77
	n	%	n	%	n	%
CR	3	18.8	3	18.8	6	37.5
PR	2	13.5	0	0	1	6.3
No response†	11	67.7	13	81.2	9	56.2
ORR (CR + PR)	5	31.3	3	18.8	7	43.8

∗

Induction therapies (n = 6) included fludarabine, cytarabine, and granulocyte colony-stimulating factor (n = 3); decitabine and venetoclax (n = 2); mitoxantrone, etoposide, and cytarabine (n = 1).

†

Includes progression, nonresponse/SD, not assessed, or received other leukemia-directed therapy.

View Large

This Feature Is Available To Subscribers Only